AstraZeneca Pharma India Limited has surrendered its factory license to the Department of Factories, Boilers, Industrial Safety and Health for cancellation. The Administrative Committee of the Board of Directors approved the decision at its meeting held on June 3, 2026.
The factory license was valid for a period from December 14, 2023 to December 31, 2026. The company had previously informed stock exchanges on June 21, 2024 about the exit from its manufacturing site and on September 2, 2025 regarding the surrender of the manufacturing license. The current factory license surrender follows these prior disclosures and is a further step in completing the regulatory exit process.
The disclosure was submitted to BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company provided the required particulars in line with the SEBI circular CFD-POD2 dated January 30, 2026, as an annexure to the regulatory filing.
AstraZeneca Pharma India Limited stated that the impact and relevance of the license surrender to the listed entity is not applicable. The company further stated there is no actual impact, monetary or otherwise, and no corrective actions have been taken following the surrender of the key license.
The factory license was initially granted on December 14, 2023 and was valid up to December 31, 2026. The surrender to the Department of Factories, Boilers, Industrial Safety and Health follows the company's decision to cease manufacturing operations at the site.
The surrender completes the regulatory formalities related to the company's exit from manufacturing at the site. AstraZeneca Pharma India Limited continues to operate its distribution, marketing, and other business activities in the country.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.